PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/NJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses unmet needs of patients with moderate to severe psoriasis and the clinical potential of targeting the TYK2 pathway as a novel nonbiologic oral therapeutic option. Upon completion of this accredited CE activity, participants should be better able to: Explain the role of the JAK-STAT signaling pathway in the pathophysiology of psoriasis, Summarize efficacy and safety data related to current and emerging kinase inhibitors for the treatment of psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and guidelines, recognizing the role of nonbiologic therapies in addressing the burden of disease and comorbidities in individual patients.

Go online to PeerView.com/WUP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice. Upon completion of this accredited CE activity, participants should be better able to: Discuss current challenges and new developments in the management of patients with hemophilia A and B, Review the mechanism of action of RNA interference and the role of novel, investigational nonfactor replacement therapies in hemophilia A and B, Evaluate the safety and efficacy profiles and clinical trial data for emerging nonfactor, nongene therapies for treating patients with hemophilia A and B with or without inhibitors.

Go online to PeerView.com/KXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hyperlipidemia discuss clinical evidence and guideline recommendations for the treatment of hyperlipidemia, for both primary and secondary prevention of CV events in patients with ASCVD. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Identify novel mechanisms of action and safety-efficacy evidence for approved and emerging investigational lipid-lowering therapies that target PCSK9, Select an appropriate lipid-lowering therapy including available and emerging agents, alone or in combination for providing guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.

Go online to PeerView.com/FNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, leading experts explore the benefits and limitations of newer potassium binders, such as patiromer and sodium zirconium cyclosilicate, and share evidence-based strategies for managing hyperkalemia to improve patient outcomes. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of hyperkalemia in patients with HF and/or CKD, Differentiate current agents for the management of hyperkalemia according to their mechanisms of action, Apply current guidelines and best-available evidence to the management of hyperkalemia in patients with HF and/or CKD, Employ evidence-based strategies for care coordination among the multidisciplinary team members to reduce the risk of readmission for hyperkalemia in patients with HF and/or CKD.

Go online to PeerView.com/KCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Over the past decade, the understanding of atopic dermatitis (AD) pathogenesis has evolved, giving way to numerous potential therapeutic targets. During this time, Janus kinase (JAK) inhibitors—a new class of medications—have also emerged. While the JAK-signal transducer and activator of transcription (JAK-STAT) pathway did not seem to be an obvious target early on, JAK inhibitors are likely to be the next generation of agents FDA approved for the treatment of moderate to severe AD. Indeed, JAK inhibitors are demonstrating benefit across multiple dermatologic diseases and constitute a promising frontier for dermatologic therapy overall. In this activity, based on a recent live web broadcast, our expert faculty examine the complex pathogenesis that underlies AD, focusing on the rationale for development of novel therapeutic approaches. In addition, key information (eg, mechanism of action, side-effect profiles, and dosing) for these new and emerging agents for moderate to severe AD will be provided, as well as the most up-to-date efficacy and safety data and practical considerations for clinical use. Upon completion of this accredited CE activity, participants should be better able to: Recognize recent insights into the pathogenesis of atopic dermatitis (AD) that have led to the development of new molecules targeting key cytokine signaling pathways, Evaluate recent safety and efficacy data related to emerging treatment options for moderate to severe AD, identifying potential implications for patient care, Develop strategies to identify candidates for newer therapeutic options and overcome barriers to achieving treatment goals in patients with moderate to severe AD.

Go online to PeerView.com/MXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care. Upon completion of this accredited CE activity, participants should be better able to: Apply criteria for the diagnosis of narcolepsy with or without cataplexy, Evaluate evidence regarding the role of oxybate formulations in the treatment of adults and children who have narcolepsy with or without cataplexy, including mechanistic effects on the underlying pathophysiology, Incorporate oxybate formulations as part of individualized regimens for treating narcolepsy, with or without cataplexy, considering comorbid conditions, disease burden, patient preferences, and quality of life.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/EME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss recent updates to recommendations in the diagnosis, surveillance, and management of tuberous sclerosis complex. Upon completion of this activity, participants should be better able to: Utilize clinical and genetic diagnostic criteria to identify patients with tuberous sclerosis complex (TSC) early in the disease course, Employ updated consensus recommendations for the surveillance of patients with TSC throughout the course of their disease, Apply updated consensus recommendations for the management of patients with specific disease manifestations associated with TSC.

Go online to PeerView.com/DXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric rheumatology discusses contemporary approaches to improve the care of patients with polyarticular juvenile idiopathic arthritis. Upon completion of this activity, participants should be better able to: Identify the clinical manifestations of polyarticular juvenile idiopathic arthritis (pJIA), Employ appropriate inclusion and exclusion criteria to facilitate an early and accurate diagnosis of pJIA, Recognize the mechanism of action, efficacy, and safety of current treatment approaches to pJIA, Select appropriate treatment for individual patients with pJIA in accordance with current evidence and expert recommendations, considering disease activity and severity as well as patient/caregiver needs and preferences.

Go online to PeerView.com/VWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting. Upon completion of this accredited CE activity, participants should be better able to: Identify best practices and current recommendations for diagnosing patients with migraine, including risk-stratification strategies for performing a differential diagnosis in the emergency department (ED); Apply evidence-based criteria and screening tools to accurately diagnose patients presenting to the ED with migraine; Summarize data on the efficacy, safety, and tolerability of agents currently available for the acute treatment and prevention of migraine; Employ strategies to help coordinate outpatient care and integrate current therapies into personalized management plans for acute treatment and prevention of migraine.